Evidence map›Paper›PMID 20422053›Full record

ArticlePloS one2010

Rapid progressing allele HLA-B35 Px restricted anti-HIV-1 CD8+ T cells recognize vestigial CTL epitopes.

Christian B Willberg, Keith E Garrison, R Brad Jones, Duncan A Meiklejohn, Gerald Spotts, Teri J Liegler, Mario A Ostrowski, Annika C Karlsson, Frederick M Hecht, Douglas F Nixon

Erratum issuedAbstract read
In one paragraph

Article in PloS one, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed.

  1. CD8Heliyon · 2024
    Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Genomic architecture of HIV-1 infection: current status & challenges.The Indian journal of medical research · 2013
    Review
  8. Article
  9. Article
  10. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors.

Christian B WillbergDivision of Experimental Medicine, Department of Medicine, University of California San Francisco, San Francisco, California, United States of America.
Keith E Garrison
R Brad Jones
Duncan A Meiklejohn
Gerald Spotts
Teri J Liegler
Mario A Ostrowski
Annika C Karlsson
Frederick M Hecht
Douglas F Nixon

Funding

Transmission and Persistence of CTL and Drug Resistance MutationsP01AI071713 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI HECHT, FREDERICK M · 2007 to 2011
$14.3M
IMMUNOLOGIC &VIROLOGIC FEATURES OF EARLY HIV INFECTIONU01AI041531 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI LEVY, JAY A · 1997 to 2006
$13.0M
Chemoprophylaxis and HIV-Host InteractionsR01AI062333 · NIAID · J. DAVID GLADSTONE INSTITUTES · PI GRANT, ROBERT M. · 2004 to 2011
$6.2M
Mechanisms Blocking HIV-1 SuperinfectionR01AI056988 · NIAID · J. DAVID GLADSTONE INSTITUTES · PI GRANT, ROBERT M. · 2004 to 2007
$3.1M
Viral Tropism and Immune Control in HIVR21AI065241 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI NIXON, DOUGLAS F · 2006 to 2007
$433k
NIAID NIH HHS AI056988NIAID NIH HHS AI41531NIAID NIH HHS AI62333NIAID NIH HHS AI65241NIAID NIH HHS AI71713NIAID NIH HHS P01 AI071713NIAID NIH HHS R01 AI056988NIAID NIH HHS R01 AI062333NIAID NIH HHS R21 AI065241NIAID NIH HHS U01 AI041531
6 · The paper itself

Abstract

backgroundThe HLA-B*35-Px allele has been associated with rapid disease progression in HIV-1 infection, in contrast to the HLA-B*35-Py allele. METHODOLOGY/PRINCIPAL

findingsImmune responses to two HLA-B*35 restricted HIV-1 specific CTL epitopes and their variants were followed longitudinally during early HIV-1 infection in 16 HLA-B*35+ individuals. Subjects expressing HLA-B*35-Px alleles showed no difference in response to the consensus epitopes compared to individuals with HLA-B*35-Py alleles. Surprisingly, all the HLA-B*35-Px+ individuals responded to epitope-variants even in the absence of a consensus response. Sequencing of the viral population revealed no evidence of variant virus in any of the individuals. CONCLUSIONS/SIGNIFICANCE: This demonstrates a novel phenomenon that distinguishes individuals with the HLA-B*35-Px rapid progressing allele and those with the HLA-B*35-Py slower progressing allele.

Indexed as

AllelesCD4 Lymphocyte CountCD8-Positive T-LymphocytesDisease ProgressionEpitopes, T-LymphocyteGenetic VariationHIV-1HIV InfectionsHLA-B35 AntigenHumansLongitudinal StudiesT-Cell Antigen Receptor SpecificityT-Lymphocytes, CytotoxicViral LoadEpitopes, T-LymphocyteHLA-B35 Antigen

Identifiers

PMID20422053
PMCPMC2858076

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.